Natural berberine-derived azolyl
ethanols as new structural antibacterial
agents were designed and synthesized for fighting with dreadful bacterial
resistance. Partial target molecules exhibited potent activity against
the tested strains, particularly, nitroimidazole derivative 4d and benzothiazole-2-thoil compound 18b, with
low cytotoxicity both exerted strong antibacterial activities against
multidrug-resistant Escherichia coli at low concentrations as 0.007 and 0.006 mM, respectively. Meanwhile,
the active compounds 4d and 18b possessed
the ability to rapidly kill bacteria and observably eradicate the E. coli biofilm by reducing exopolysaccharide content
to prevent bacterial adhesion, which was conducive to alleviating
the development of E. coli resistance.
Preliminary mechanistic explorations suggested that the excellent
antibacterial potential of molecules 4d and 18b might be attributed to their ability to disintegrate membrane, accelerate
ROS accumulation, reduce bacterial metabolism, and intercalate into
DNA groove. These results provided powerful information for the further
exploitation of natural berberine derivatives against bacterial pathogens.
Dextran as a drug carrier for inhibiting cancer cells effectively reduces the toxic and side effects of the drug in the biological body. Targeting improves the concentration of active substance around the target tissue, which reduces damage to other heavy organs and other normal tissues. Dextran will be a potential carrier for the delivery of antitumor drugs in the future, which provides the possibility of slow-release chemotherapy and targeted drug delivery. Herein, the preparation and drug delivery of dextran-drug complex were summarized and discussed in detail.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.